Objectives: Early diagnosis of upper gastrointestinal (UGI) amyloidosis and the establishment of appropriate treatment and follow-up strategies remains challenging. This study aimed to elucidate the endoscopic characteristics and clinical courses of patients with isolated UGI amyloidosis. Methods: We retrospectively reviewed 11 patients diagnosed with isolated UGI amyloidosis at Chonnam National University Hospital and Chonnam National University Hwasun Hospital. None of the patients exhibited systemic involvement or multiple myeloma. Clinical data, including endoscopic features, presenting symptoms, and outcomes such as disease progression and mortality, were analyzed. Results: The cohort included seven males (63.6%) and four females (36.4%), with a median age of 72 (37–82) years. Isolated gastric amyloidosis was identified in four patients, and five patients had disease confined to the duodenum. Two patients (18.2%) presented with gastric or duodenal involvement. Endoscopic findings were heterogeneous, with diffuse yellowish linear lesions being the most frequently observed in four patients (36.4%). Histopathological analysis revealed AA amyloidosis in three patients, whereas five patients exhibited only amorphous deposits without amyloid A, amyloid P, or light chains. Six patients (54.5%) were asymptomatic at diagnosis, whereas gastrointestinal bleeding was observed in two patients (18.2%). Only one patient (9.1%) experienced disease progression that necessitated systemic chemotherapy. The mean follow-up duration was 20 months, and the 3-year mortality rate was 9.1%. Conclusions: Isolated UGI amyloidosis is a heterogeneous condition that can be easily misdiagnosed. Familiarity with the characteristic endoscopic features and natural disease course is essential for appropriate management.
20 April 2026 in Journal of Digestive Cancer Research
Je Seong Kim, Won Jae Lee, Chae June Lim, Young Eun Seo, Chan Muk Im, Hyung Hoon Oh, Ki-Hyun Kim, Young Eun Joo. Journal of Digestive Cancer Research 2026;14:115-9. https://doi.org/10.52927/jdcr.2026.14.1.115
20 August 2026 in Journal of Digestive Cancer Research
Chan-Muk Im, Chae-June Lim, Je-Seong Kim, Young-Eun Seo, Hyung-Hoon Oh, Sung-Bum Cho, Wan-Sik Lee, Myung-Giun Noh, Young-Eun Joo. Journal of Digestive Cancer Research 2026;14:191-5. https://doi.org/10.52927/jdcr.2026.14.2.191
Background/Objectives: Real-world data in high-risk patients remain limited; this study evaluated survival, safety, and prognostic factors in this patient group. Methods: This multicenter study retrospectively reviewed 783 patients who received Ate/Bev from 2022–2024 across South Korea. High-risk patients (n = 252, 32.2%) were defined by main portal vein tumor thrombus (Vp4), tumor occupancy ≥50% of liver volume, or bile duct invasion. Propensity score matching (PSM) was performed to balance host-related factors between the high-risk and non-high-risk (n = 531) groups. Results: After PSM (251 pairs, n = 502), overall survival (median 10.4 vs. 14.9 months; HR 1.57, 95% CI 1.28–1.92, p < 0.001) and progression-free survival (median 6.0 vs. 6.8 months; HR 1.29, 95% CI 1.08–1.53, p = 0.009) remained significantly worse in the high-risk group. Objective response (25.1% vs. 19.9%, p = 0.200) and disease control rates (71.7% vs. 76.5%, p = 0.262) were comparable. Among 103 responders with documented response-onset dates, an exploratory complete-case analysis showed a numerically shorter duration of response in the high-risk group, although the difference did not reach statistical significance (median, 7.1 vs. 11.3 months; HR, 1.57; 95% CI, 0.97–2.55; p = 0.065). Conclusions: Ate/Bev achieved similar antitumor response rates in high-risk and non-high-risk patients, but survival remained poorer in the high-risk group. High-risk status therefore did not preclude antitumor activity with Ate/Bev.
20 August 2026 in Journal of Digestive Cancer Research
Chae-June Lim, Chan-Muk Im, Je-Seong Kim, Young-Eun Seo, Won-Jae Lee, Hyung-Hoon Oh, Gihyun Kim, Sung-Bum Cho, Wan-Sik Lee, Young-Eun Joo. Journal of Digestive Cancer Research 2026;14:160-8. https://doi.org/10.52927/jdcr.2026.14.2.160